As hubby wrote, it is not important to be a biotech expert to see that 2-73 is almost certain to be approved for AD or that 3-71 is looking pretty good so far for schizophrenia. We all rely on people with more expertise that we have to make good decisions. 58 experts - all of whom know more about the pathology and treatment of AD patients than we do (even those of us whose families have suffered) - tell us 2-73 is a game-changer. The OLE confirms it. The EMA has accepted the MAA application which is close to a blessing. The EU member countries are negotiating pricing now.
It does help to understand the various areas of function in biotech in order to assess operational risks and market opportunity, and to understand clinical process to assess likelihood of success. I have first hand experience with nearly everything except for drug product sales, business development (M&A, in/out-licensing, partnerships), real estate, and legal. I don't think that you or investor and a couple of other posters here are barking up the right trees in general - and don't really understand why you participate here if you don't really want to be constructive.
Market Data 
Markets 
AI
